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Abstract
Background: To examine the effects on LDL cholesterol of the combined use of statins and phytosterols/-stanols,
in vivo studies and clinical trials are necessary. However, for a better interpretation of the experimental data as well
as to possibly predict cholesterol levels given a certain dosing regimen of statins and phytosterols/-stanols a more
theoretically based approach is helpful. This study aims to construct a mathematical model to simulate reductions
in low-density lipoprotein (LDL) cholesterol in persons who combine the use of statins with a high intake of
phytosterols/-stanols, e.g. by the use of functional foods.
Methods and Results: The proposed model includes the cholesterol pool size in the liver and serum levels of very
low-density lipoprotein (VLDL) cholesterol. Both an additional and a multiplicative effect of phytosterol/-stanol
intake on LDL cholesterol reduction were predicted from the model. The additional effect relates to the decrease
of dietary cholesterol uptake reduction, the multiplicative effect relates to the decrease in enterohepatic recycling
efficiency, causing increased cholesterol elimination through bile. From the model, it was demonstrated that a daily
intake of 2 g phytosterols/-stanols reduces LDL cholesterol level by about 8% to 9% on top of the reduction
resulting from statin use. The additional decrease in LDL cholesterol caused by phytosterol/-stanol use at the
recommended level of 2 g/d appeared to be similar or even greater than the decrease achieved by doubling the
statin dose.
Conclusion: We proposed a simplified mathematical model to simulate the reduction in LDL cholesterol after
separate and combined intake of statins and functional foods acting on intestinal (re)absorption of cholesterol or
bile acids in humans. In future work, this model can be extended to include more complex (regulatory)
mechanisms.
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Background
Increased total cholesterol and low-density lipoprotein
(LDL) cholesterol levels represent a major risk for ather-
osclerosis and coronary heart disease (CHD). Lipid-low-
ering drugs, of which the hydroxymethylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors (statins)
have shown to be the most effective, reduce morbidity
and mortality in patients with CHD [1-3]. Since the last
decade of the 20
th century, more interest has been given
to changing dietary habits, for example with the appear-
ance of the so-called functional foods. Dairy products
enriched with phytosterols/-stanols are one of the best
known and most used functional foods to lower elevated
total and LDL cholesterol levels. Phytosterols/-stanols
are thought to compete with cholesterol for solubilisa-
tion into mixed micelles, the transport vehicles for cho-
lesterol across the intestinal wall. Consequently, the
intestinal (re)absorption of cholesterol is reduced, faecal
output is increased and total and LDL cholesterol levels
are lowered by 6% and 10%, respectively [4,5]. Due to
the rising public awareness of health and nutritional
improvement, and the mounting evidence of the
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any medium, provided the original work is properly cited.effectiveness of phytosterols/-stanols, it is conceivable
that in the near future an increasing number of people
will combine their statin therapy with these functional
foods.
To examine the effects on total and LDL cholesterol
levels of the combined intake of statins and phytoster-
ols/-stanols, in vivo studies and clinical trials are neces-
sary. However, for a better interpretation of the
experimental data as well as to possibly predict choles-
terol levels given a certain dosing regimen of statins and
phytosterols/-stanols a more theoretically based
approach is helpful.
The present study focuses on the combined effect of
atorvastatin and phytosterols/-stanols. However, our
model can easily be applied to other statins and similar
acting functional foods (e.g. soluble dietary fibres) as
well. Moreover, based on certain genetic variants asso-
ciated with cholesterol absorption and production an
individual’s specific reduction in total and LDL choles-
terol can be predicted.
Methods
We propose a simplified mathematical model to esti-
mate reductions in LDL cholesterol after separate and
combined intake of statins and phytosterols/-stanols
(Figure 1). A list of model variables and abbreviations is
presented in Table 1. Since LDL is the product of very
low-density lipoprotein (VLDL) delipidation and VLDL
also transports, although to a lesser extent than endo-
genous triglycerides,[6] cholesterol from the liver to the
blood circulation, our model includes the modelling of
the metabolism of VLDL cholesterol as well. Also a
hepatic cholesterol pool is accounted for in the model,
because VLDL cholesterol secretion depends on choles-
terol pool size. In the next section, we first describe a
basic model which includes the modelling of the choles-
t e r o lp o o l ,V L D Lc h o l e s t e r o la n dL D Lc h o l e s t e r o l .S u b -
sequently, this basic model is reformulated to express
reductions in LDL cholesterol level dependent of statin
and/or phytosterol/-stanol intake. Published scientific
literature was used to estimate specific model para-
meters. In the second part of the present study (Results
section), we tested the appropriateness of our model
using available published experimental data.
Basic cholesterol model
Modelling of the cholesterol pool
A mass balance is considered with cholesterol input
from endogenously produced cholesterol PC and from
cholesterol taken up from the diet, IC.O n l yaf r a c t i o n
fabs of dietary cholesterol is assumed to be taken up
across the gut wall, and consequently the uptake of
dietary cholesterol is UC = fabs·IC.T h em a s sb a l a n c e
output consists of produced VLDL cholesterol, choles-
terol cleared by elimination of excess cholesterol
through bile and cholesterol needed to produce bile
salts. For simplicity, we neglect the reverse cholesterol
transport mediated by high-density lipoprotein (HDL)
and the existence of a hepatic cholesteryl ester pool
that might be involved in cholesterol homeostasis.
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Figure 1 Simplified scheme of LDL cholesterol metabolism in humans. For detailed description of the model see text. The definition of the
model variables are summarised in Table 1.
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is not considered.
The model considers only steady state levels of choles-
terol, VLDL cholesterol and LDL cholesterol. For a
steady cholesterol level, the input of cholesterol should
be balanced by its output. Clearance of cholesterol by
VLDL cholesterol formation, bile excretion and bile salts
formation is assumed to be non-saturated and is
described by the product of clearance rates and steady
cholesterol level.
Of the daily amount of VLDL cholesterol formation,
kVCV ·C, the product of steady cholesterol level C with
VLDL particles V and association rate kVC,af r a c t i o n
fback is reabsorbed into the liver. It consists of VLDL
cholesterol that is not used for LDL cholesterol produc-
tion and of LDL cholesterol. The other fraction 1- fback
is taken up by the extrahepatic tissues, of which part is
excreted through HDL cholesterol, which will not be
considered in this modelling approach. As a
consequence of this recycling, the effective clearance
rate of cholesterol to VLDL cholesterol is (1- fback)·kVCV.
The amount of cholesterol eliminated through bile salts
formation is ksalt·C.
Likewise, because it is assumed that not only dietary
cholesterol but also cholesterol cleared by bile with a
daily amount of kbile·C is reabsorbed through enterohe-
patic recycling, the effective clearance rate of cholesterol
through bile is (1- fabs)·kbile.
As we consider the effect of statins and phytosterols/-
stanols on LDL cholesterol levels, the model becomes
slightly more complicated. First, it is assumed that
reduced cholesterol production PC is related to the
external daily dose S of statins, PC =P C(S). Second, it is
assumed that the reduced cholesterol fraction absorbed
from dietary cholesterol intake relates to the amount of
intake of phytosterols/-stanols (PS), fabs = fabs(PS).
In the steady state the input cholesterol PC(S)+fabs
(PS)·IC is balanced by cleared cholesterol, which is the
Table 1 Model variables and abbreviations used in the study
Model variable Abbreviation
Endogenously produced cholesterol PC
Dietary cholesterol intake IC
External daily statin dose S
External daily free phytosterol/-stanol dose PS
(Steady state) concentration of free cholesterol in the liver C
VLDL particles V
Absorbed cholesterol fraction fabs
Fraction of produced VLDL cholesterol that re-enters the liver fback
Association rate of VLDL particles and free cholesterol to VLDL cholesterol kVC
Excretion of cholesterol from the cholesterol pool by bile kbile
Excretion of cholesterol through the formation of bile salts ksalts
Reduction in cholesterol pool size RC
Cholesterol pool concentration in absence of statins and phytosterols/-stanols C0
Endogenous produced cholesterol in absence of statins and phytosterols/-stanols PC,0
Uptake of dietary cholesterol in absence of statins and phytosterols/-stanols UC,0
Absorbed cholesterol fraction in absence of statins and phytosterols/-stanols fabs,0
Reduction in endogenous cholesterol production RP
Reduction in fraction of cholesterol uptake from the diet RU
Ratio of exponential rates of different cholesterol elimination routes rk
VLDL cholesterol production rate PVC
Transformation rate of VLDL cholesterol to LDL cholesterol kVL
(Steady state) VLDL cholesterol concentration VC
Maximum rate of change in (V)LDL cholesterol due to saturated uptake process Vmax
Michaelis-Menten constant in (V)LDL cholesterol model KM
(Steady state) LDL cholesterol concentration LC
LDL cholesterol production from VLDL cholesterol PLC
Clearance rate of LDL cholesterol through non-saturated process kn
Maximal achievable reduction in endogenous cholesterol production RP, max
Half maximum reduction statin dose SP, 1/2
Maximal achievable reduction in fraction of cholesterol uptake from the diet RU, max
Half maximum reduction phytosterol/-stanol dose PSU, 1/2
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cholesterol level((1- fback) kVCV)+( 1 -fabs(PS)) kbile
+ksalts)·C(S, PS). Thus, the steady cholesterol level is:
C(S,PS)=
PC(S)+fabs(PS) · IC
(1 − fback) · kVCV +( 1− fabs(PS)) · kbile + ksalts
(1)
It should be noted that it is implicitly assumed that
there is no interaction between statins and phytoster-
ols/-stanols consumed, i.e. both compounds work simul-
taneously, independent of each other.
Modelling of VLDL cholesterol level
In the modelling of the cholesterol pool (equation (1)) it
is assumed that the production of VLDL cholesterol PVC
is proportional to both the concentration of VLDL parti-
cles and the free cholesterol level: PVC =k VCV ·C(S, PS).
Like for cholesterol, a steady state level VC(S, PS)o f
VLDL cholesterol follows from the balance between its
production and its clearance. VLDL cholesterol is
assumed to be cleared due to the production of LDL
cholesterol with daily clearance of kVL·VC(S, PS)a n d
due to saturated receptor-mediated uptake from blood
into the liver and extrahepatic tissues [6]. Receptor-
mediated uptake is assumed to follow Michaelis-Menten
kinetics with a maximum clearance rate Vmax and a
saturation constant KM.
Therefore, a steady state VLDL cholesterol level leads
to the following mass balance for LDL cholesterol:
PVC = kVCV · C(S,PS)=kVL · VC(S,PS)+
Vmax · VC(S,PS)
KM + VC(S,PS) (2)
The steady state VLDL cholesterol level can be
obtained by solving the implicit equation for VC(S, PS).
The explicit expression for VC is deduced in Appendix
1. Note that of the Michaelis-Menten saturated clear-
ance of VLDL cholesterol from blood a fraction fback
goes into the liver. The complementary fraction 1- fback
goes into extrahepatic tissues (Figure 1).
Modelling of LDL cholesterol level
In the modelling of the VLDL cholesterol level (equation
(2)), we assumed that the production of LDL cholesterol
PLC is proportional to the steady VLDL cholesterol level:
PLC =k VL·VC(S, PS). LDL cholesterol is assumed to be
cleared with rate kn through a non-saturated process
and by saturated uptake from blood into the liver and
extrahepatic tissues by the same receptors as for the
saturated uptake of VLDL cholesterol [6]. Hence, the
mass balance for steady state LDL cholesterol is:
PLC = kVLVC(S,PS)=kn · LC(S,PS)+
Vmax · LC(S,PS)
KM + LC(S,PS)
(3)
from which the LDL cholesterol level can be obtained
by solving the implicit equation (3) for LC(S, PS). The
explicit expression for LC can be found in Appendix 1.
Similar as for VLDL cholesterol, a fraction fback of the
Michaelis-Menten saturated clearance of LDL choles-
terol from blood goes into the liver. The complementary
fraction 1- fback goes into extrahepatic tissues (Figure 1).
Vmax,K M are the same maximum elimination rate and
saturation constant of the Michaelis-Menten saturated
uptake of VLDL cholesterol from blood into the liver.
These constants are assumed to be the same, but this
assumption is not essential.
Cholesterol reduction model
Modelling cholesterol reduction by statins and
phytosterols/-stanols
When it is assumed that statins and phytosterols/-sta-
nols work independently of each other, the reduction
in the cholesterol pool size can be expressed in terms
of a reduction:RP (S)=PC (S)/PC,0 in cholesterol pro-
duction caused by statin use and a reduction: RU (PS)
= fabs(PS)/fabs,0 in dietary cholesterol absorption across
the gut wall caused by phytosterol/-stanol use. PC,0
and fabs,0 denote the cholesterol production rate and
absorption fraction in absence of statins or phytoster-
ols/-stanols. From equation (1) it is derived in Appen-
dix 2 that the corresponding reduction RC(S, PS)i n
the steady state cholesterol level is the product of the
reduction due to a decrease in enterohepatic efficiency
(first factor at the right side of equation (4)) and a
weighted mean of the reduction due to a decrease in
cholesterol production and uptake (second factor at
the right side of equation (4)):
Rc (S,PS) =
C(S,PS)
C0
=
ρk +1− fabs,0
ρk +1− fabs (PS)
      
ﬁrstfactor
×
⎛
⎜
⎜ ⎜
⎝
ﬁrstterm
      
Rp (S)
1+UC,0
 
PC,0
+
secondterm
      
RU (S)
1+PC,0
 
UC,0
⎞
⎟
⎟ ⎟
⎠
      
secondfactor
(4)
Here, like for cholesterol production and absorption,
C0 and UC,0denote, respectively, the cholesterol pool
concentration and dietary uptake in absence of statins
and phytosterols/-stanols. In the first factor at the right
side, the ratio rk denotes the proportion of cholesterol
elimination through VLDL cholesterol production and
bile salts production to cholesterol elimination through
bile excretion, as introduced in Appendix 2.
T h ef o l l o w i n gr e m a r k ss h o u l db em a d er e g a r d i n gt h i s
model. First, the effectiveness of statins or phytosterols/-
stanols to lower cholesterol production is determined by
the ratio of the contribution of endogenous produced
cholesterol and the contribution of dietary cholesterol
uptake to the cholesterol pool. Thus, when dietary cho-
lesterol uptake is increased, the effectiveness of statins
(first term in the second factor) is reduced with respect
to the effectiveness of phytosterols/-stanols. Obviously,
the opposite holds true for the effectiveness of phytos-
terols/-stanols.
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lesterol has an additional effect in total cholesterol pool
reduction (the second term in the second factor at the
right side of equation (4)) and a multiplicative one (first
factor at the right side of equation (4)). The additional
effect relates to the decrease of dietary cholesterol
uptake reduction, whereas the multiplicative effect
relates to the decrease in enterohepatic recycling effi-
ciency, causing increased cholesterol elimination
through bile.
Third, the additional reduction caused by statin and
phystosterol/-stanol use is a weighted sum of the reduc-
tion in cholesterol production and cholesterol absorp-
tion because 1/(1+ PC,0 /UC,0 ) +1/(1+ UC,0 /PC,0 )=1 .
Formulating reduction as a Michaelis-Menten process
In the model described above, we aim to associate
reductions in the cholesterol pool size to reductions in
LDL cholesterol level. In order to estimate the reduction
in the cholesterol pool size following statin intake, RP(S),
a reduction model has to be assumed. From experimen-
tal in vitro data from Shum et al [7]. a reasonable
model assumption is obtained as follows. Shum et al.
related the concentration of atorvastatin in plasma to
the inhibition of the enzyme HMG-CoA reductase in
vitro. We assumed a Michaelis-Menten saturated inhibi-
tion process. This model was fitted to their experimental
data and provided a nearly perfect fit (Figure 2).
From this experimental in vitro result, it is proposed
that the reduction in endogenously produced cholesterol
is most likely Michaelis-Menten saturated with adminis-
tered statin dose as well:
RP(S)=1−
RP,max · S
SP,1/2 + S
(5)
where RP, max ≤ 1 determines the maximum achievable
reduction and SP, 1/2 is the half maximum reduction sta-
tin dose.
Based on the fact that cholesterol uptake is receptor-
mediated,[8] we assumed that the reduction in the frac-
tion absorbed cholesterol is like:
RU(PS)=1−
RU,max · PS
PSU,1/2 + PS
(6)
where RU, max ≤ 1 determines the maximum achiev-
able reduction and PSU,1 / 2is the half maximum reduc-
tion phytosterol/-stanol dose.
Thus, the total reduction in cholesterol pool size after
combined intake of statins and phytosterols/-stanols is
obtained by substituting equations (5) and (6) in equa-
tion (4):
RC(S,PS)=
ρk +1− fabs,0
ρk +1−
 
1 − RU,max · PS/
 
PSU,1/2 + PS
  
· fabs,0
×
 
1 −
PC,0
PC,0 + UC,0
·
RP,max · S
SP,1/2 + S
−
UC,0
PC,0 + UC,0
·
RU,max · PS
PSU,1/2 + PS
  (7)
In this derivation we used 1/(1+ UC,0 /PC,0 )+ 1/(1+
PC,0 /UC,0 )=1
Parameter value estimation
The reduced steady state cholesterol concentration can
be obtained from a given daily dose of statins or phytos-
terols/-stanols by applying the reduction model
Figure 2 Simulated dose-response relation between in vitro plasma atorvastatin concentration (ng/ml) and hydroxymethylglutaryl-
coenzyme A (HMG-CoA) inhibition (%) in humans. Maximum inhibition is 97.8% and the concentration at half maximum inhibition is 1.64
(ng/ml). Solid symbols present data by Shum et al. [7]
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tion, the reduced steady VLDL cholesterol level can be
derived by solving equation (2), and subsequently the
reduced LDL cholesterol level can be derived by solving
equation (3). However, to be applicable in practice,
model parameters should be known. In this section all
parameters of our model are quantified based on data in
the literature.
Basic cholesterol model parameters
It is assumed that the liver produces PC,0= 1000 mg
cholesterol per day [9-12]. Furthermore, we assumed a
dietary cholesterol intake of IC = 400 mg/d, of which a
fraction of 50% (fabs,0= 0.5)[9,13] is taken up in the
liver (UC,0= 200 mg/d). The same fraction is supposed
to be recycled through enterohepatic recycling of cho-
lesterol excreted with bile. The final contribution to
liver cholesterol input is assumed to be 70% of produced
VLDL cholesterol (fback = 0.7) [14].
It is assumed that the amount of cholesterol excreted
with bile is 1000 mg/d[9,13,15] and consequently, 500
mg/d re-enters the liver. The rate of excretion through
the formation of bile salts is 400 mg/d [16]. Concerning
the local liver balance, the input is 1000 (produced cho-
lesterol, PC ,0)p l u s2 0 0( u p t a k e ,UC,0 ) plus 500
(recycled, (1- fabs,0 )·kbile·C0) plus 700 (back transport,
fback·kVCV·C0) making a total of 2400 mg/d. The output
is 1000 (bile, kbile·C0) plus 400 (bile salts, ksalts·C0), and
making a total of 2400 mg/d, plus the production of
1000 mg VLDL cholesterol per day (VLDL cholesterol,
kVCV·C0). Moreover, as the elimination from the liver is
proportional to the production rates of bile salts, choles-
terol in bile and VLDL cholesterol, the ratio of these
production rates is ksalts: kbile: kVCV = 0.4: 1: 1.
From Sahlin et al.[ 1 7 , 1 8 ]w ee s t i m a t e dt h ef r e ec h o -
lesterol content in liver to be 55 nmol/mg microsomal
protein. Together with a microsomal protein content of
45 mg/g liver[19] this amounts to 2500 μmol/kg liver
which equals 960 mg free cholesterol/kg liver. From this
free cholesterol concentration and the daily bile excre-
tion, one can derive kbile = 1000/960 = 1.04, kVCV =
1.04 and ksalts = 0.416.
Dietschy et al. [6] report LDL cholesterol model para-
meter values in humans. When assuming a subject of 70
kg, these values are Vmax = 1340 mg/d, KM =9 0m g / d l ,
kn = 5 dl/d and PLC = 910 mg/d. Based on these values,
as t e a d yc h o l e s t e r o ll e v e lLC =6 7m g / d lr e s u l t sf r o m
equation (3).
The VLDL:LDL:HDL cholesterol ratio was estimated
to be 1:8:3 [20]. Thus the corresponding VLDL level is
8.4 mg/dl. As the LDL cholesterol production rate is
equal to kVL·VC (equation (3)), kVL = 108 (dl/d). From
equation (2) a VLDL cholesterol production of 1020
mg/d can be calculated. Above it is assumed to be 1000
mg/d which shows a consistency error of 2% only.
Cholesterol reduction model parameters
From the ratio between the effective clearances, intro-
duced in the basic cholesterol model parameters section,
one can derive that the ratio rk in equation (4) is 0.7.
The four remaining parameters RP, max, SP,1 / 2 , RU, max,
PSU,1 / 2are unknown and were fitted to optimise their
likelihood in comparing modelled LDL cholesterol
reduction induced by cholesterol reduction to LDL cho-
lesterol reduction data. Thus, given an estimation of the
four cholesterol reduction model parameters, the reduc-
tion in steady state cholesterol is calculated, the result-
ing reduction in VLDL cholesterol is determined from
equation (2) and the resulting reduction in LDL choles-
terol is determined from equation (3).
To simulate the appropriateness of our model,
reduced levels are compared with the experimental data
for separate intakes of atorvastatin[21] and phytoster-
ols/-stanols [22]. For this procedure we use for RP, max,
SP,1 / 2data from a recent meta-analysis of Berry et al.
[21] that shows experimentally determined in vivo LDL
cholesterol reduction due to atorvastatin dose. For RU,
max, PSU,1 / 2we use data presented in Demonty et al.
[22] showing experimentally determined in vivo LDL
cholesterol reduction due to intake of free phytosterols/-
stanols, i.e. phytosterols/-stanols not in esterified form.
Finally, we simulate reductions after combined intake of
atorvastatin and phytosterols/-stanols.
Results
Separate intake
LDL cholesterol reduction by atorvastatin
We applied equation (7) together with the correspond-
ing VLDL and LDL cholesterol levels equations (2) and
(3) to data in Berry et al. [21] in a LDL cholesterol
reduction model using the model parameters given
above. The unknown parameter values in equation (7)
were estimated through fitting the maximum reduction
RP, max and the statin dose SP,1 / 2when half maximum
reduction is reached.
Figure 3 shows the comparison of the resulting LDL
cholesterol reduction model to the data in Berry et al.
[21] Parameter values are RP, max = 0.544 (standard error
(SE) = 0.033) and half reduction dose SP,1 / 2=6 . 7( S E=
1.4) mg/d. Given the parsimony of dose levels and scat-
tering of data, a good comparison between the model
and the experimental results is obtained (R
2 = 0.70).
LDL cholesterol reduction by phytosterols/-stanols
We applied equation (7) together with the correspond-
ing VLDL and LDL cholesterol levels equations (2) and
(3) to data in Demonty et al.[ 2 2 ]i naL D Lc h o l e s t e r o l
reduction model. The unknown parameter values in
equation (7) were estimated through fitting the maxi-
mum reduction RU, max and the free phytosterol/-stanol
dose PSU, 1/2 when half maximum reduction is reached.
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cholesterol reduction model to the data of Demonty et
al. [22] Parameter values are RU, max = 0.221 (SE =
0.039) and half reduction dose PSU,1 / 2=1 . 7 8( S E=
0.69) mg/d. The model shows reasonable agreement
with the published experimental data (R
2 = 0.17).
Combined intake
LDL cholesterol reduction by combined use of atorvastatin
and phytosterols/-stanols
The model is applied to LDL cholesterol reduction due
to the combined intake of statins and phytosterols/-sta-
nols. For subjects with a daily intake of 0, 20, 40 and 80
Figure 3 Simulated reduction (%) in LDL cholesterol after treatment with different doses of atorvastatin. The solid line shows the fit to
the model and symbols represent experimental data from Berry et al. [21] Values for the Michaelis-Menten parameters are: effective maximum
LDL cholesterol reduction (RP, max) = 0.544 and half maximum reduction statin dose (SP, 1/2) = 6.7 mg/d. The dashed lines show the 5% and 95%
uncertainty range in reduction obtained by correlated sampling (correlation coefficient r = 0.88) of RP, max and SP, 1/2 from their covariance
matrix.
Figure 4 Simulated reduction (%) in LDL cholesterol after treatment with different doses of phytosterols/-stanols. The solid line shows
the fit to the model and symbols represent experimental data from Demonty et al. [22] Values for the Michaelis-Menten parameters are:
effective maximum LDL cholesterol reduction (RU, max) = 0.221 and half maximum reduction phytosterol/-stanol dose (PSU, 1/2) = 1.78 mg/d. The
dashed lines show the 5% and 95% uncertainty range in reduction obtained by correlated sampling (correlation coefficient r = 0.98) of RU, max
and PSU, 1/2 from their covariance matrix.
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total reduction in LDL cholesterol as a function of daily
phytosterol/-stanol intake. For the daily recommended
intake level of 2 g free phytosterols/-stanols (equivalent
to 3.3 g/d phytosterol/-stanol esters), the additional
reduction is 4.2% for a daily statin dose of 80 mg, 4.5%
for a daily statin dose of 40 mg, 4.8% for a daily statin
dose of 20 mg and 7.8% with no statin intake. Thus, the
reduction in LDL cholesterol caused by additional phy-
tosterol/-stanol intake decreases with increasing daily
atorvastatin dose. However, when considering the addi-
tional decrease as a percentage of the LDL cholesterol
level already reduced due to statin intake, the additional
decrease ranges from 7.8% (no statin intake) to 8.6% (80
mg daily statin dose). Randomised controlled trials in
which patients on statin therapy were treated daily with
1.8 to 6 g phytosterol or -stanol esters have shown
reductions in the same order of magnitude, i.e. between
6.1% and 10.3% [23-28].
The reduction in enterohepatic recycling contributes
for 68%, 58%, 56% and 55% of the total decrease in
LDL cholesterol levels at daily statin doses of 0, 20, 40
and 80 mg, respectively. At the same recommended
phytosterol/-stanol intake level of 2 g/d, the additional
decrease in LDL cholesterol by physterols/-stanols for a
daily statin dose of 20 mg (4.8%) is equal to the addi-
tional decrease by doubling daily statin dose to 40 mg
(5.3%). For a daily statin dose of 40 mg the additional
decrease in LDL cholesterol by physterols/-stanols
(4.5%) is 30% larger than the additional decrease by
doubling daily statin dose to 80 mg (3.2%).
Discussion
In this paper, a mathematical model is presented that
simulates the reductions in LDL cholesterol after sepa-
rate and combined intake of atorvastatin and phytoster-
ols/-stanols in humans. We demonstrated that a daily
intake of 2 g phytosterols/-stanols reduces LDL choles-
terol level by about 8% to 9% on top of the reduction
resulting from statin use. This level of reduction is con-
sistent with the findings of randomised controlled trials
[23-28]. The additional decrease in LDL cholesterol
caused by phytosterol/-stanol use at the recommended
level of 2 g/d appeared to be similar or even greater
than the decrease achieved by doubling the statin dose,
a finding that has been observed previously in human
trials [23,29]. The reduction in LDL cholesterol level
due to phytosterol/-stanol use results from a decrease in
the intestinal uptake of dietary cholesterol (additional
effect) and a reduction in enterohepatic recycling (multi-
plicative effect). For daily statin doses of 20 mg or more,
the contribution of the enterohepatic recycling reduc-
tion is 55% or more. When no statin is used, this contri-
bution is 68%.
Mathematical models provide a valuable means of
interpreting experimental data and improving the ability
to predict the response to a given treatment. Other
modelling studies have focused on cholesterol metabo-
lism, but are merely aimed at answering questions on
the cellular level or tend to focus on specific areas of
cholesterol metabolism, such as the fluid dynamics of
lipid accumulation on the arterial wall or the chemical
kinetics of LDL oxidation [30-32].
20 mg/d atorvastatin
40 mg/d atorvastatin
80 mg/d atorvastatin
No atorvastatin 
Figure 5 Simulated reduction (%) in LDL cholesterol after combined treatment with different doses of free phytosterols/-stanols and
atorvastatin in humans. The lines from upper to lower show LDL cholesterol reduction for subjects that are exposed to no atorvastatin, or
daily doses of 20, 40 or 80 mg atorvastatin, respectively.
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effects of the cholesterol-lowering drug atorvastatin and
functional foods with phytosterols/-stanols in humans
were modelled. Yet, this model can easily be applied to
other statins and similar acting (functional) foods as
well. Products with soluble dietary fibres, for example,
are also known to lower total and LDL cholesterol by
reducing the intestinal (re)absorption of cholesterol and
bile acids, although they work by a different mechanism
as phytosterols/-stanols [4,33,34]. Moreover, individuals’
specific reductions in total and LDL cholesterol can be
predicted, based on certain genetic variants. For exam-
ple, the ratio of cholesterol synthesis to cholesterol
absorption varies between individuals and is an impor-
tant determinant for the cholesterol pool size [35]. Also
mutations in the LDL receptor gene causing familial
hypercholesterolaemia can be modelled by varying the
parameter Vmax.
There are a few possible directions for improving our
model. First, the model could be extended by including
the up- and down regulatory mechanisms involving the
LDL receptors. Nonetheless, since we assumed that the
clearing of (V)LDL cholesterol from the blood follows
Michaelis-Menten kinetics, we implicitly included recep-
tor-mediated uptake in the model. Also other regulatory
control pathways were disregarded, such as the existence
of a hepatic cholesteryl ester pool that might be
involved in cholesterol homeostasis and the regulatory
loop in the synthesis of LDL receptors [30]. Another
extension would include reverse cholesterol transport
mediated by HDL [20]. Moreover, the proposed model
assumes that the reducing effects of statins and func-
tional foods are independent of each other. Although
this is likely the case for the combination of phytoster-
ols/-stanols and statins,[22,24,36,37] it is uncertain
whether this applies for other food-drug combinations.
It has, for example, been proposed that soluble dietary
fibres reduce the intestinal uptake of statins [38,39]. Our
model should be extended to include such an
interaction.
In conclusion, we proposed a simplified mathematical
model to simulate the reduction in LDL cholesterol
after separate and combined intake of statins and func-
tional foods acting on intestinal (re)absorption of cho-
lesterol or bile acids in humans. In future work, this
model can be extended to include more complex (regu-
latory) mechanisms.
Appendix 1
Steady VLDL cholesterol concentration
The mass balance equation (2) can be rewritten as a
quadratic equation in VC:
kVL · VC2 +( Vmax + kVL · KM − kVCV · C) · VC − KM · kVCV · C =0
Here, we suppress the dependencies on statin admin-
istration S and dietary phytosterol/-stanol intake PS.
A quadratic equation has two solutions, but the only
physicochemical relevant solution for which the VLDL
cholesterol concentration is non-negative is:
VC =
1
2kVL
(kVCV · C − kVL · KM − Vmax
+
 
(kVCV · C − kVL · KM − Vmax)
2 +4 kVL · KM · kVCV · C
 
Steady LDL cholesterol concentration
Like for VLDL cholesterol, the mass balance equation
(3) can be rewritten as:
kn · LC2 +( Vmax + kn · KM − kVL · VC) · LC − KM · kVL · VC =0
with as solution:
LC =
1
2kn
(kVL · VC − kn · KM − Vmax
+
 
(kVL · VC − kn · KM − Vmax)
2 +4 kn · KM · kVL · VC
 
Appendix 2
Reduction in steady state cholesterol
The reduction in steady state cholesterol level is:
RC(S,PS)=
C(S,PS)
C0
=
 
PC(S)+fabs(PS) · IC
 
/
 
(1 − fback) · kVCV +( 1− fabs(PS)) · kbile + ksalts
 
 
PC,0 + fabs,0 · IC
 
/
 
(1 − fback) · kVCV +( 1− fabs,0) · kbile + ksalts
 
=
(1 − fback) · kVCV +( 1− fabs,0) · kbile + ksalts
(1 − fback) · kVCV +( 1− fabs(PS)) · kbile + ksalts
·
PC(S)+fabs(PS) · IC
PC,0 + fabs,0 · IC
=
ρk +1− fabs,0
ρk +1− fabs(PS)
·
 
PC(S)
PC,0 + UC,0
+
fabs(PS) · IC
PC,0 + fabs,0 · IC
 
=
ρk +1− fabs,0
ρk +1− fabs(PS)
·
 
RP(S)
1+UC,0/PC,0
+
RU(PS)
1+PC,0/UC,0
 
In the third line, the ratio of clearance rates rk =( ( 1 -
fback)·kVCV + ksalts)/kbile is introduced. In this line also
one instance of fabs,0 ·IC is substituted by UC,0 .I nt h e
fourth line the definition of production reduction and,
after dividing out intake IC, of uptake reduction is
substituted.
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